Merck shares plunge as company pauses Gardasil vaccine shipments in China, hurting 2025 outlook
Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...
STAT2d
Merck’s earnings miss focused attention on Gardasil. The real issue is Keytruda
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
FiercePharma3d
Merck halts Gardasil shipments to China, withdraws $11B sales target as demand nosedives
The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...
Merck's Gardasil Vaccine Slowdown In China Bites Again, Stock Falls On Weak 2025 Outlook
Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the ...
Fact-checking Warren's claim about RFK Jr.'s work on vaccine lawsuits
During health secretary nominee Robert F. Kennedy Jr.'s Jan. 29 Senate confirmation hearing, Sen. Elizabeth Warren, D-Mass., ...
Legal experts say RFK Jr.'s move to give financial interest in vaccine lawsuits to family is 'not unusual'
Amid scrutiny over Robert F. Kennedy Jr.'s pledge to divest his financial stake in vaccine lawsuits to his family, legal ...
BioSpace3d
Merck’s Gardasil Woes Grow as China Trade War Heats Up
Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.
Merck Posts Quarterly Profit on Sales Growth
The drug company’s outlook for 2025 and a slide in sales of its HPV vaccine, Gardasil, hit shares.